1;Preface;42;Contents;53;1 Principles of Medical Oncology;183.1;1.1 Epidemiology;183.2;1.2 Carcinogenesis, Molecular Tumor Biology;203.3;1.3 Hematopoiesis and Development of Hematological Neoplasia;243.4;1.4 Prevention and Screening;273.5;1.5 Classification of Diseases and ICD System;313.6;1.6 Tumor Classification and TNM System;343.7;1.7 Indications for Tumor Therapy;363.8;1.8 Performance Status of Tumor Patients (" Performance Status Scales");383.9;1.9 Response Evaluation in Solid Tumors;393.10;1.10 Common Toxicity Criteria ( NCI);423.11;1.11 Assessing the Quality of Life of Tumor Patients;473.12;1.12 Evidence- based Medicine ( EBM), Guidelines and Quality Management;493.13;1.13 Electronic Media;524;2 Special Diagnostics;564.1;2.1 Cytogenetics and Fluorescence In Situ Hybridization ( FISH);564.2;2.2 Molecular Diagnosis;594.3;2.3 Gene Expression Analysis using Microarrays;624.4;2.4 Tumor Markers;644.5;2.5 CD Antigens and Immunocytological Diagnosis;684.6;2.6 HLA System and MHC;795;3 Pharmacology and Pharmacotherapy;825.1;3.1 Basic Principles of Chemotherapy;825.2;3.2 Cytostatic Drugs;865.2.1;3.2.1 Characteristics of Clinically Used Cytostatic Drugs;885.2.2;3.2.2 Check List Cytostatic Treatment;1485.2.3;3.2.3 Drug Dosage Calculation Based on Body Surface Area ( BSA);1495.2.4;3.2.4 Dose Adjustment of Cytostatic Drugs;1515.2.5;3.2.5 Chemotherapy During Pregnancy and Lactation;1585.2.6;3.2.6 Selected Cytostatic Drug Incompatibilities;1605.2.7;3.2.7 Preparation and Stability of Cytostatics;1635.3;3.3 Hormone Therapy;1705.3.1;3.3.1 Characterization of Hormone Treatments in Oncology;1735.4;3.4 Cytokines;1875.5;3.5 Monoclonal Antibodies;1955.6;3.6 Specific Protein Kinase Inhibitors (" Targeted Therapies");2055.7;3.7 Drug Development and Clinical Studies;2155.8;3.8 Pharmacogenetics and Pharmacogenomics;2186;4 Supportive Treatment;2216.1;4.1 Antiemetic Prophylaxis and Therapy;2216.2;4.2 Antibiotic Treatment and Neutropenic Fever;2286.3;4.3 Growth Factors;2356.4;4.4 Nutrition in Cancer Patients;2426.5;4.5 Pain Control;2526.6;4.6 Fatigue;2586.7;4.7 Bisphosphonates;2606.8;4.8 Malignant Effusions;2666.8.1;4.8.1 Malignant Pleural Effusion;2676.8.2;4.8.2 Malignant Pericardial Effusion;2716.8.3;4.8.3 Malignant Ascites;2746.9;4.9 Transfusion Therapy;2786.10;4.10 Human Sperm Cryopreservation;2886.11;4.11 Cryopreservation of Human Pronuclear Oocytes;2916.12;4.12 Sexual Dysfunction;2936.13;4.13 Physiotherapy and Sports Medicine;2956.14;4.14 Principles of Oncology Nursing Care;2986.15;4.15 Psycho- oncological Care;3036.16;4.16 Rehabilitation;3067;5 Particular Treatment Procedures;3107.1;5.1 Hematopoetic Stem Cell Technology ( Harvesting, Culture, Purging);3107.2;5.2 Autologous Hematopoetic Stem Cell Transplantation;3137.3;5.3 Allogeneic Hematopoetic Stem Cell Transplantation;3197.4;5.4 Granulocyte Transfusion;3267.5;5.5 Immunotherapy;3287.6;5.6 Gene Therapy;3327.7;5.7 Inhibition of Angiogenesis;3367.8;5.8 Developmental Therapeutics;3398;6 Hematology and Hemostasis;3448.1;6.1 Aplastic Anemia;3448.2;6.2 Neutropenia and Agranulocytosis;3498.3;6.3 Thrombocytopenia;3538.3.1;6.3.1 Immune ( Idiopathic) Thrombocytopenic Purpura ( ITP, Werlhof's Disease);3568.3.2;6.3.2 Heparin- induced Thrombocytopenia ( HIT);3608.3.3;6.3.3 Thrombotic Microangiopathies ( TTP- HUS);3628.4;6.4 Anemia;3658.4.1;6.4.1 Hypochromic Anemia;3688.4.2;6.4.2 Megaloblastic Anemia;3728.4.3;6.4.3 Hemolytic Anemia;3768.4.4;6.4.4 Normochromic Anemia;3868.5;6.5 Coagulation Disorders;3888.5.1;6.5.1 Acquired Coagulation Disorders;3938.5.2;6.5.2 Factor VIII Deficiency ( Hemophilia A);3988.5.3;6.5.3 Factor IX Deficiency ( Hemophilia B);4018.5.4;6.5.4 Von Willebrand's Disease ( VWD);4038.5.5;6.5.5 Disseminated Intravascular Coagulation ( DIC);4068.6;6.6 Thromboembolism and Thrombophilia;4109;7 Hematological Neoplasia;4179.1;7.1 Acute Leukemias;4179.2;7.2 Myelodysplastic Syndrome ( MDS);4409.3;7.3 Myeloprol